- Pre-clinical development of particulate malaria transmission-blocking vaccines
I completed my undergraduate degree in Biological Sciences at University of Edinburgh in 2010 followed by completion of MSc in Immunology at University of Oxford in 2011. In 2015, I finished my DPhil in Clinical Medicine at the Jenner Institute.
I took part in the Plasmodium falciparum transmission-blocking vaccine (TBV) research lead by Dr Sumi Biswas and the focus of my DPhil study was to construct and produce Pfs25 based particulated protein vaccines in an attempt to increase the antigen immunogenicity. Antigen multimerisation using a platform named IMX313 was particularly immunogenic in the preclinical studies and both quantitative and qualitative better antibody response was achieved.
Part of my current task is to investigate the compatibility of IMX313 with other TBV antigen candidates.
Brune KD, Buldun CM, Li Y, Taylor IJ, Brod F, Biswas S, Howarth M. Dual Plug-and-Display Synthetic Assembly Using Orthogonal Reactive Proteins for Twin Antigen Immunization. Bioconjugate Chemistry 2017 28(5), 1544-1551. doi: 10.1021/acs.bioconjchem.7b00174.
Li, Y. et al. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology. Sci. Rep. 6, 18848; doi: 10.1038/srep18848 (2016).